---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016865"
form_type: "8-K"
ticker: "GERN"
cik: "0000886744"
company_name: "GERON CORP"
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T01:15:14.717843+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Geron Q2 net loss $28.1M; IMerge Phase 3 top-line results expected early Jan 2023

## Summary
- Net loss of $28.1M ($0.07 per share) vs $29.6M ($0.09) in Q2 2021; revenue $73K.
- Cash and marketable securities $220M as of June 30, 2022; debt facility expanded to $125M with $50M additional non-dilutive capital available in 2023.
- FY2022 GAAP operating expenses guided $155-165M; non-GAAP $140-150M.
- IMerge Phase 3 top-line results in lower risk MDS on track for early Jan 2023; U.S. NDA planned H1 2023, EU MAA H2 2023.
- Pipeline expansion: new studies in R/R AML and frontline MF starting H2 2022; IMpactMF interim analysis in 2024.

## SEC filing metadata
- accession: 0000950170-22-016865
- form_type: 8-K
- ticker: GERN
- cik: 0000886744
- company_name: GERON CORP
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886744/000095017022016865/0000950170-22-016865-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886744/000095017022016865/gern-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016865
- JSON: https://secwatch.observer/filing/0000950170-22-016865.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016865.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.